13F Holdings
中文EN

SANA Sana Biotechnology, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1770121 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY36.3%
TTM EPS YoY45.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-79.5%
ROA-36.8%
ROIC (approx.)-109.1%
Asset turnover—

Leverage & solvency

Liabilities / assets52.0%
Debt / equity0.00x
Current ratio1.77x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-1.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$131.98M$215.67M$261.81M$285.88M$248.63M
SG&A expense$44.30M$64.04M$73.30M$71.56M$50.41M
Operating income-$250.32M-$272.72M-$293.14M-$272.56M-$356.91M
Pretax income————-$355.93M
Income tax$0————
Net income-$244.17M-$266.76M-$283.25M-$269.48M-$355.93M
EBITDA-$237.52M-$257.22M-$275.64M-$256.96M-$345.81M
EPS (basic)-0.96-1.16-1.46-1.43-2.14
EPS (diluted)-0.96-1.16-1.46-1.43-2.14
Weighted avg. shares (diluted)253.23M230.89M194.54M188.34M166.43M
Balance sheet
Cash & equivalents$71.87M$131.40M$133.52M$187.27M$261.85M
Short-term investments$66.51M$24.93M$71.68M$247.20M$297.97M
Current assets$148.68M$160.81M$213.51M$444.44M$558.10M
PP&E, net$26.91M$77.31M$70.69M$66.92M$65.46M
Goodwill$140.63M$140.63M$140.63M$140.63M$140.63M
Intangibles$59.20M$59.20M$59.20M$59.20M$59.20M
Total assets$416.89M$501.02M$565.30M$822.72M$1.13B
Current liabilities$78.73M$45.43M$64.49M$111.50M$99.23M
Total liabilities$256.01M$250.52M$277.79M$323.40M$400.90M
Shareholders' equity$160.88M$250.50M$287.51M$499.31M$728.50M
Shares outstanding266.73M223.92M197.86M191.02M184.93M
Cash flow statement
Operating cash flow-$143.83M-$223.15M-$253.58M-$290.05M-$251.05M
Capital expenditure$938,000$33.43M$20.03M$20.88M$29.86M
Free cash flow-$144.77M-$256.58M-$273.61M-$310.93M-$280.92M
Investing cash flow-$40.24M$17.45M$172.01M$210.56M-$245.80M
Financing cash flow$128.73M$199.75M$31.65M$4.91M$631.75M
Depreciation & amortization$12.80M$15.50M$17.50M$15.60M$11.10M
Stock-based compensation$25.46M$37.68M$35.53M$38.34M$22.36M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.